Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase NA 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 116Cyclophosphamide 104venetoclax 89fludarabine 85Azacitidine 81fludarabine phosphate 70Rituximab 59Filgrastim 44Peripheral Blood Stem Cell Transplantation 39Methotrexate 39Dexamethasone 35Decitabine 35Busulfan 32Etoposide 31Tacrolimus 30Mycophenolic Acid 29Granulocyte Colony-Stimulating Factor 28Lenalidomide 27Whole-Body Irradiation 26Idarubicin 26Vincristine 25Melphalan 24Cyclosporine 24Clofarabine 24Mitoxantrone 22Bortezomib 21Alemtuzumab 21ibrutinib 19ruxolitinib 17aldesleukin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pravastatin × Other hematologic neoplasm × Clear all
NCT01342887 2017-07-02

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Fred Hutchinson Cancer Center

Phase 1/2 Terminated
6 enrolled 6 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡